

October 31, 2016

To  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

**Scrip Code: 524558**

To  
The National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E)  
Mumbai - 400 001

**Scrip Code: NEULANLAB  
Series: EQ**

Dear Sirs,

**Ref: Our letters dated August 27, 2016 and August 30, 2016**

Further to our letter dated October 12, 2016, we would like to inform you that the Board of Directors of the Company, at the meeting scheduled to be held on Friday, November 4, 2016, inter alia, would also consider a draft Scheme of Amalgamation and Arrangement between Neuland Laboratories Limited ("the Company"), Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited, along with the Un-audited financial results of the Company for the quarter ended September 30, 2016.

Also, as informed vide our letter dated October 12, 2016, the Trading Window would remain closed till November 6, 2016 (inclusive) for transactions in the shares of the Company.

This is for your Information and records.

Thanking you,

Yours faithfully,  
For Neuland Laboratories Limited



**Sarada Bhamidipati  
Company Secretary**